A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

BMC Health Services Research

Yot Teerawattananon²  Pitsaphun Werayingyong²  Tawesak Tanwandee¹  Usa Chaikledkaew²  Narisa Tantai² 

[1] Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok 10700, Thailand;Health Intervention and Technology Assessment Program (HITAP), 6th floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Road, Muang, Nonthaburi 11000, Thailand

关键词: Treatment;    Cost-utility analysis;    Hepatitis B;    Chronic disease;   

Others  :  1132741
DOI  :  10.1186/1472-6963-14-170

 received in 2013-09-21, accepted in 2014-04-09,  发布年份 2014

【 摘 要 】

Background

Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. In order to fill this gap in policy research, the objective of this study was to compare the cost-utility of each drug therapy (Figure 1) with palliative care in patients with HBeAg-positive CHB.

Methods

A cost-utility analysis using an economic evaluation model was performed to compare each drug treatment for HBeAg-positive CHB patients. A Markov model was used to estimate the relevant costs and health outcomes during a lifetime horizon based on a societal perspective. Direct medical costs, direct non-medical costs, and indirect costs were included, and health outcomes were denoted in life years (LYs) and quality-adjusted life years (QALYs). The results were presented as an incremental cost effectiveness ratio (ICER) in Thai baht (THB) per LY or QALY gained. One-way sensitivity and probabilistic sensitivity analyses were applied to investigate the effects of model parameter uncertainties.

Results

The ICER values of providing generic lamivudine with the addition of tenofovir when drug resistance occurred, generic lamivudine with the addition of tenofovir based on the road map guideline, and tenofovir monotherapy were -14,000 (USD -467), -8,000 (USD -267) , and -5,000 (USD -167) THB per QALY gained, respectively. However, when taking into account all parameter uncertainties in the model, providing generic lamivudine with the addition of tenofovir when drug resistance occurred (78% and 75%) and tenofovir monotherapy (18% and 24%) would yield higher probabilities of being cost-effective at the societal willingness to pay thresholds of 100,000 (USD 3,333) and 300,000 (USD 10,000) THB per QALY gained in Thailand, respectively.

Conclusions

Based on the policy recommendations from this study, the Thai government decided to include tenofovir into the NLED in addition to generic lamivudine which is already on the list. Moreover, the results have shown that the preferred treatment regimen involves using generic lamivudine as the first-line drug with tenofovir added if drug resistance occurs in HBeAg-positive CHB patients.

【 授权许可】

   
2014 Tantai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hepatitis B [http://www.who.int/immunization/topics/hepatitis_b/en/ webcite]
• [2]Dan YY, Aung MO, Lim SG: The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008, 2(3):284-295.
• [3]Lai CL, Yuen MF: Chronic hepatitis B–new goals, new treatment. N Engl J Med 2008, 359(23):2488-2491.
• [4]van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T: Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51(1):73-80.
• [5]Chen W, Hou JL: Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2009, 17(8):569-573.
• [6]Buti M, Casado MA, Calleja JL, Salmeron J, Aguilar J, Rueda M, Esteban R: Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2006, 23(3):409-419.
• [7]Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A: Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assess 2009, 13(35):1-172. iii
• [8]Costa AM, Li G, Nita ME, Araujo ES: Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil. Braz J Infect Dis 2008, 12(5):368-373.
• [9]Calcagno JI, Augustovski F, Gadano A, Souto A, Yuan Y: Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B. Acta Gastroenterol Latinoam 2008, 38(4):260-273.
• [10]Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG: Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008, 27(12):1240-1252.
• [11]Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG: Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007, 25(11):963-977.
• [12]Yuan Y, Iloeje UH, Hay J, Saab S: Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008, 14(1):21-33.
• [13]Buti M, Brosa M, Casado MA, Rueda M, Esteban R: Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009, 51(4):640-646.
• [14]Spackman DE, Veenstra DL: A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008, 26(11):937-949.
• [15]Arnold E, Yuan Y, Iloeje U, Cook G: Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 2008, 6(4):231-246.
• [16]Yuan Y, Iloeje U, Li H, Hay J, Yao GB: Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008, 11(Suppl 1):S11-S22.
• [17]You JH, Chan FW: Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opin Pharmacother 2008, 9(15):2673-2681.
• [18]Aggarwal R, Ghoshal UC, Naik SR: Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India 2002, 15(6):320-327.
• [19]Brooks EA, Lacey LF, Payne SL, Miller DW: Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 2001, 7(7):677-682.
• [20]Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM: Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005, 142(10):821-831.
• [21]Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK: HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008, 11(2):131-138.
• [22]Crowley S, Tognarini D, Desmond P, Lees M, Saal G: Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002, 17(2):153-164.
• [23]Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK: Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Eur J Gastroenterol Hepatol 2007, 19(8):631-638.
• [24]Sun X, Qin WX, Li YP, Jiang XH: Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol 2007, 22(9):1369-1377.
• [25]Liver Soceity Thailand: Thailand Consensus Recommendations for Management of Chronic Hepatitis B and C 2009. 2010.
• [26]Liaw YF: 2008 APASL guidelines for HBV management. Liver Reasearch Unit, Chang Gung Memorial Hospital and Chang Gung University, Taipei, Taiwan 2008.
• [27]Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352(26):2682-2695.
• [28]European Association For The Study Of The Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50(2):227-242.
• [29]Cooper N, Coyle D, Abrams K, Mugford M, Sutton A: Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. J Health Serv Res Policy 2005, 10(4):245-250.
• [30]Tantai N, Lerdkiattikorn P, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon T: Clinical Efficacy of Chronic Hepatitis B Treatment for Patients with HBeAg-Positive Indirect Comparison: Network Meta-Analysis. Mahidol J Pharm Sci 2012, 39(2):46-49.
• [31]McMahon BJ, Holck P, Bulkow L, Snowball M: Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135(9):759-768.
• [32]Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 437 Study Group: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348(9):808-816.
• [33]Jang JW, Lee YC, Kim MS, Lee SY, Bae SH, Choi JY, Yoon SK: A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. J Viral Hepat 2007, 14(3):169-175.
• [34]Xu B, Hu DC, Rosenberg DM, Jiang QW, Lin XM, Lu JL, Robinson NJ: Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003, 18(12):1345-1352.
• [35]Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112(2):463-472.
• [36]Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Sola R: Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004, 40(5):823-830.
• [37]Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmerón J, Caballero-Granado FJ, García-García JA, Grupo Andaluz para el Estudio de las Enfermedades Infecciosas: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005, 41(4):779-789.
• [38]Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL: Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007, 12(8):1295-1303.
• [39]Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T, Shoji B, Takaki A, Iwasaki Y, Sakaguchi K, Shiratori Y, Yamamoto K: A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 2008, 23(5):794-803.
• [40]Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351(15):1521-1531.
• [41]Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ: Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010, 52(2):176-182.
• [42]Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM: Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005, 12(4):386-392.
• [43]Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37(4):748-755.
• [44]Piao C-Y: Lamivudine Treatment in Patients with HBV-related Hepatocellular Carcinoma-using an Untreated, Matched Control Cohort. Acta Med Okayama 2005, 59(5):217-224.
• [45]The Thai Working Group on Burden of Disease and Injuries: Burden of Disease and Injuries in Thailand: Priority Setting for Policy. 2002.
• [46]Ministry of Public Health: Reference Price Database of the Drugs and Medical Supplies Information Center (DMSIC). 2010.
• [47]Reimbursement List of Medical Services The Comptroller General's Department, Ministry of Finance2009.
• [48]Thongsawat S: Resource utilization and direct medical cost of chronic hepatitis C (CHC) in Thailand: a heavy but manageable economic burden. ISPOR 12th Annual European Congress: 24-27 October 2009 2009; Paris, France 2009.
• [49]Minimum wage rate [http://www.labour.go.th/en/ webcite]
• [50]Comsumer Price Index in February 2010 [http://www.indexpr.moc.go.th/price_present/cpi/data/index_47.asp?list_month=02&list_year=2553&list_region=country webcite]
• [51]Permsuwan U, Guntawongwan K, Buddhawongsa P: Handling time in economic evaluation studies. J Med Assoc Thai 2008, 91(suppl 2):S53-S58.
• [52]Rates of Exchange of Commercial Banks in Bangkok Metropolis [http://www2.bot.or.th/statistics/ReportPage.aspx?reportID=123&language=eng webcite]
• [53]PPP conversion factor, private consumption [http://data.worldbank.org/indicator/PA.NUS.PRVT.PP webcite]
• [54]Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH: The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value Health 2008, 11(3):527-538.
• [55]National List of Essential Drugs: Appropriate Threshold in Thailand. National List of Essential Drug Meeting on December 20, 2007 [Chaiyanadnarainthorn Meeting Room, Thai Food and Drug Administration; 2550]
• [56]2012 National List of Essential Drugs [http://www.nlem.in.th/sites/default/files/ratchakitcha_1-55.pdf webcite]
• [57]Viread Prescribing Guidelines U.S. Food and Drug Administration 2006.
• [58]Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125(6):1714-1722.
• [59]Duarte-Rojo A, Heathcote EJ: Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010, 3(2):107-119.